Reframe Daily: Home workout aids ataxia; early Alzheimer’s blood tests; kidney-saving antibody

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A simple home workout helped people with cerebellar ataxia walk better; two blood tests (including p-tau217 with a short tablet test) flagged very early Alzheimer’s; and a new antibody approach protected tiny kidney blood vessels and reduced scarring in animal studies.

Christin’s note: appreciating being able to breathe through my nose tho still coughing quite a bit too much to record a video, unfortunately! Truly grateful for my health when it is available quietly in the background 🙏 I hope you all enjoy your daily breaths!

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A simple home workout helped people with cerebellar ataxia walk and feel better.

Home Training for Cerebellar Ataxias: A Randomized Clinical Trial

Market readiness: 😊😊😊😊😊 (home aerobic training is available now; can be prescribed and monitored with routine clinical follow-up) 

Good news: A quick blood test (p-tau217) identified people with very early Alzheimer’s changes before symptoms.

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

Market readiness: 😊😊😊 (lab-developed blood tests exist in the US now, but broad screening and FDA-cleared assays are still developing) 

Good news: A short self-administered tablet test plus a blood test helped primary-care clinics pick up Alzheimer’s earlier.

Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers

Market readiness: 😊😊😊 (tools and blood biomarkers are emerging and piloted in clinics, but need wider validation and coverage before routine use)

Good news: A new antibody strategy protected tiny kidney blood vessels and reduced scarring in disease models—pointing to a future drug approach.

TIE2 activation by antibody-clustered endogenous angiopoietin-2 prevents capillary loss and fibrosis in experimental kidney disease

Market readiness: 😊 (preclinical proof-of-concept in animals; human trials would be next) 

Thank you for taking the time to take care of yourself and your loved ones.